Skip to content
value.today

Zynex, Inc.: financial analysis

Ratios worked out from 10 fiscal years of Zynex, Inc.'s statements, compared with 102 companies in Medical Devices.

Operating margin, 2024
3.1%
Medical Devices: -8.2%
Return on equity, 2024
7.3%
Medical Devices: -16.8%
Revenue growth, 3 years a year, 2024
13.9%
Medical Devices: 10.8%
Free cash flow margin, 2024
6.3%
Medical Devices: -1.9%

Zynex, Inc. scorecard#

Passes 12 of the 17 checks that could be worked out: strongest in shareholder returns (3 of 4), weakest in profitability (3 of 5). Fiscal year 2024.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth4 of 6
    • ✓Revenue grew in the newest year4.4%Revenue up 4.4% in fiscal 2024.
    • ✓Revenue up more than 5% a year over three years13.9%13.9% a year over the three years to fiscal 2024.
    • ✓Faster growth over three years than its peers' median13.9%13.9% a year against Medical Devices's median of 10.8% (73 companies).
    • ✗Earnings per share grew in the newest year0.09 vs 0.27Diluted EPS 0.09 in fiscal 2024 against 0.27 the year before (report's currency).
    • ✗Net income higher than five years earlier$3 M$3 M in fiscal 2024 against $9 M in 2019.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2024.
  • Profitability3 of 5
    • ✓Profitable in the newest year$3 MNet income $3 M in fiscal 2024.
    • ✓Profitable in each of the last five years5 of 5Profitable in 5 of the five years to fiscal 2024.
    • ✓Operating margin above its peers' median3.1%3.1% against Medical Devices's median of -8.2% (86 companies).
    • ✗Return on equity above 15%7.3%7.3% in fiscal 2024.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier3.1%3.1% in fiscal 2024 against 17.2% in 2021.
  • Financial health2 of 2
    • ✓Short-term assets cover short-term liabilities4.5×Current ratio 4.46 at the end of fiscal 2024.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2024.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns3 of 4
    • ✓Pays a dividendYesPaid dividends in fiscal 2024.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • ✓Dividends under 75% of net income0.3%Dividends were 0.3% of net income in fiscal 2024.
    • ✓Share count up no more than 2% in a year-10.6%Diluted shares down 10.6% in fiscal 2024.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • ✗Free cash flow covers dividends and buybacks$12 MFree cash flow $12 M against $16 M paid out in fiscal 2024.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2024 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Strengths

  • Revenue has grown 10 years in a row.
  • The share count fell 10.6% in the year (buybacks).

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

6of 8(1 of the nine tests cannot be worked out from the statements on file, so there is no full score)
  • Made a profityes
  • Operations brought in cashyes
  • Return on assets roseno
  • Cash from operations exceeds profityes
  • Long-term debt fell against assetsnot on file
  • Current ratio roseno
  • No new shares issuedyes
  • Gross margin roseyes
  • Asset turnover roseyes

Where the return on equity comes from

The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.

Net margin1.6%Asset turnover1.49×Assets to equity3.17×Return on equity7.3%

Profitability#

Zynex, Inc.: profitability by fiscal year
Fiscal yearTrend20242023202220212020Median of peersAhead of
Gross margin79.5%79.2%79.8%79.0%78.3%62.9%87%
Operating margin3.1%5.9%14.5%17.2%12.8%-8.2%64%
Net margin1.6%5.3%10.8%13.1%11.3%-10.4%62%
Return on equity7.3%17.3%24.3%26.2%23.7%-16.8%71%
Return on assets2.3%7.7%13.7%16.7%18.1%-12.7%71%
Return on invested capital——37.7%41.0%—10.6%—

Growth#

Zynex, Inc.: growth by fiscal year
Fiscal yearTrend20242023202220212020Median of peersAhead of
Revenue growth4.4%16.5%21.4%62.6%76.2%10.4%30%
Revenue growth, 3 years a year13.9%32.0%51.5%59.8%50.7%10.8%54%
Revenue growth, 5 years a year33.4%42.0%46.5%57.8%47.1%15.3%85%
Net income growth-69.3%-42.9%-0.3%88.5%-4.4%5.7%8%
Earnings per share growth-66.7%-38.6%0.0%83.3%-14.3%3.3%8%

Financial strength#

Zynex, Inc.: financial strength by fiscal year
Fiscal yearTrend20242023202220212020Median of peersAhead of
Debt to equity——0.08×0.14×—0.64×—
Net debt——$-15 M$-32 M—$10 M—
Interest cover—————-3.82×—
Current ratio4.46×4.74×3.30×3.62×6.23×3.30×71%
Equity share of assets29.3%33.7%57.0%55.5%78.8%54.6%18%

Cash#

Zynex, Inc.: cash by fiscal year
Fiscal yearTrend20242023202220212020Median of peersAhead of
Free cash flow$12 M$17 M$13 M$6 M$-0 M$-3 M67%
Free cash flow margin6.3%9.0%8.4%4.9%-0.2%-1.9%67%
Cash conversion425.4%182.5%80.7%40.6%9.0%152.3%97%
Capital spending share of revenue0.3%0.7%0.3%0.5%1.2%2.5%—

Shareholder returns#

Zynex, Inc.: shareholder returns by fiscal year
Fiscal yearTrend20242023202220212020Median of peersAhead of
Dividend payout0.3%0.0%21.2%0.0%—46.1%—
Change in share count-10.6%-7.6%-0.2%2.0%13.2%4.1%98%

Efficiency#

Zynex, Inc.: efficiency by fiscal year
Fiscal yearTrend20242023202220212020Median of peersAhead of
Asset turnover1.49×1.45×1.27×1.27×1.60×0.64×95%

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Return on invested capital
Operating income after tax, as a share of debt plus equity less cash (average of the year). The tax rate is the year's own: income tax over pre-tax income.
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Revenue growth, 5 years a year
The yearly rate that takes revenue of five years earlier to this year's.
Net income growth
Net income against the year before. Only when both years were profitable.
Earnings per share growth
Diluted earnings per share against the year before. Only when both were positive.
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Capital spending share of revenue
Capital spending as a share of revenue.
Dividend payout
Dividends paid as a share of net income. Only when the year was profitable.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Zynex, Inc.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 102 companies in Medical Devices that Zynex, Inc. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Zynex, Inc.